<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364868</url>
  </required_header>
  <id_info>
    <org_study_id>GPPAD-03-POInT</org_study_id>
    <nct_id>NCT03364868</nct_id>
  </id_info>
  <brief_title>GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)</brief_title>
  <official_title>Oral Insulin Therapy for Prevention of Autoimmune Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinderkrankenhaus auf der Bult</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford, Clinical Vaccine Research and Immunisation Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GPPAD-POInT Study is designed as a randomized, placebo-controlled, double blind,
      multicentre, multinational primary prevention phase IIb study aiming to induce immune
      tolerance to beta-cell autoantigens through regular exposure to oral insulin for a period of
      29 to 32 months. The hypothesis is that regular exposure to oral insulin throughout the
      period in life where beta-cell autoimmunity usually initiates will tolerize against insulin
      and train the body's immune system to recognize the treatment product without reacting
      adversely to it in a manner seen in children who develop T1D. This immune tolerance induction
      therapy would reduce the likelihood of beta-cell autoimmunity. The study objective is to
      determine whether daily administration of oral insulin from age 4 months - 7 months until age
      3.00 years to children with elevated genetic risk for type 1 diabetes reduces the cumulative
      incidence of beta-cell autoantibodies and diabetes in childhood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The GPPAD-POInT-Study aims to determine whether daily administration of oral insulin to
      children from age 4 months - 7 months with elevated genetic risk for type 1 diabetes reduces
      the cumulative incidence of beta-cell autoantibodies and diabetes in childhood. The purpose
      of the GPPAD-POInT-Study is to induce immune tolerance to beta-cell autoantigens through
      regular exposure to oral insulin for a period of 29 to 32 months. Together with the results
      of the currently ongoing Pre-POINT-Early Study, this phase IIb study aims to investigate and
      consolidate the findings from the pilot Pre-POINT Study, namely safety and immune efficacy at
      a daily dose of 67.5 mg oral insulin. Since babies and young children will be tested in the
      GPPAD-POInT-Study, the 67.5 mg dose will be reached by dose escalation starting at 7.5 mg for
      2 months, followed by exposure to 22.5 mg for 2 months, and reaching the desired 67.5 mg
      dose. The GPPAD-POInT-Study aims to recruit 1040 children into the trial.

      The active substance for oral application is human insulin. Oral Insulin will be applied as a
      capsule containing 7.5, 22.5 and 67.5 mg of the active substance together with filling
      substance microcrystalline cellulose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The development of persistent confirmed multiple beta-cell autoantibodies</measure>
    <time_frame>elapsed time from treatment assignment (baseline) to first positive sample visit (&gt;2 beta-cell antibodies) in children who develop persistent confirmed multiple beta-cell antibodies. Primary outcome can develop any time up to last study visit at 7.5 yrs</time_frame>
    <description>development of persistent confirmed multiple beta-cell autoantibodies (defined as confirmed IAA, confirmed GADA, confirmed IA-2A, or confirmed ZnT8A in two consecutive samples, AND a confirmed second antibody from these four antibodies in one sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The development of diabetes</measure>
    <time_frame>elapsed time from random treatment assignment (baseline) to the development diabetes (date of diagnosis). This primary outcome measure can develop any time during treatment or follow-up period up to the last study visit at 7.5 years of age</time_frame>
    <description>OGTT criteria or clinical criteria for diabetes as defined by the American Diabetes Association (ADA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any persistent confirmed beta-cell autoantibody or diabetes</measure>
    <time_frame>elapsed time from treatm. assignm. (baseline) to 1st pos. sample for &gt;1 beta-cell antibody in children who developed persist. confirm. beta-cell antibodies OR diabetes onset, whichever is first. outcome can develop any time up to last visit at 7.5 yr</time_frame>
    <description>At least one confirmed autoantibody, in two consecutive samples, including GADA, IA-2A, IAA, ZnT8A, or TS7A, or diabetes as defined by the American Diabetes Association (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent confirmed IAA.</measure>
    <time_frame>elapsed time from treatment assignment (baseline) to first sample that is positive for IAA in children who develop persistent confirmed IAA. Outcome can develop any time during treatment or follow-up period up to the last study visit at 7.5 years of age.</time_frame>
    <description>Confirmed IAA in two consecutive samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent confirmed GADA.</measure>
    <time_frame>elapsed time from treatment assignment (baseline) to the first sample that is positive for GADA in children who develop persistent confirmed GADA. Outcome can develop any time up to the last study visit at 7.5 years of age</time_frame>
    <description>Confirmed GADA in two consecutive samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal glucose tolerance (AGT) defined by dysglycemia or diabetes.</measure>
    <time_frame>elapsed time from treatment assignment to the date at which abnormal glucose tolerance or diabetes is diagnosed. Outcome can develop any time up to the last study visit at 7.5 years of age</time_frame>
    <description>Dysglycemia is defined as impaired fasting plasma glucose of ≥110 mg/dL (6.1 mmol/L), or impaired 2-hour glucose of ≥140 mg/dL (7.8 mmol/L), or high glucose levels at intermediate time points on OGTT (30, 60, 90 min) levels of ≥200mg/dL (11.1 mmol/L)). Diabetes is defined according to the criteria of the American Diabetes Association (ADA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1040</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>oral insulin capsule (dose escalation using 3 dose strengths)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Insulin</intervention_name>
    <description>treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.</description>
    <arm_group_label>oral insulin capsule (dose escalation using 3 dose strengths)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).</description>
    <arm_group_label>Placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Infant between the ages of 4 months and 7 months at the time of randomization.

        2. A high genetic risk (&gt;10%) to develop beta-cell autoantibodies by age 6 years:

          1. For infants without a first degree family history of type 1 diabetes, high genetic
             risk is defined as a DR3/DR4-DQ8 or DR4-DQ8/DR4-DQ8 genotype, and a genetic risk score
             that is &gt;14.4.

          2. For infants with a first degree family history of type 1 diabetes, high genetic risk
             is defined as having HLA DR4 and DQ8, and none of the following protective alleles:
             DRB1*1501, DQB1*0503.

          3. Solid foods introduced into diet of infant

          4. Written informed consent signed by the custodial parent(s).

        Exclusion Criteria:

          1. Concomitant disease or treatment that may interfere with the assessments, as judged by
             the investigators.

          2. Any condition that could be associated with poor compliance.

          3. Any medical condition or medical condition coexisting, which, in the opinion of the
             investigator, may jeopardize the participant's safe participation in the study.

          4. Diagnosis of diabetes at the time of recruitment.

          5. Participation in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>7 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anette-G. Ziegler, Prof. Dr.</last_name>
    <phone>+49-(0)800 - 000 00 18</phone>
    <email>contact@gppad.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Achenbach, PD Dr.</last_name>
    <phone>+49-(0)800 - 000 00 18</phone>
    <email>contact@gppad.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Casteels, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Munich, Germany</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette-G. Ziegler, Prof. Dr.</last_name>
      <phone>+49-(0)800 - 000 00 18</phone>
      <email>contact@gppad.org</email>
    </contact>
    <contact_backup>
      <last_name>Peter Achenbach, Prof. Dr.</last_name>
      <phone>+49-(0)800 - 000 00 18</phone>
      <email>contact@gppad.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AUF DER BULT, Kinder- und Jugendkrankenhaus, Hanover, Germany</name>
      <address>
        <city>Hanover</city>
        <state>Lower Saxony</state>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Kordonouri, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik f. Kinder und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, CRTD/DFG-Forschungszentrum für Regenerative Therapien, Dresden, Germany</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Berner, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw, Department of Paediatrics, Warsaw, Poland</name>
      <address>
        <city>Warsaw</city>
        <zip>00-001</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnieszka Szypowska, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Dep. of Clinical Sciences Malmo, Skane University Hospital SUS, University Hospital MAS, Malmo, Sweden</name>
      <address>
        <city>Malmö</city>
        <zip>202 13</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helena Elding Larsson, Assoc. Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics Clinical Vaccine Research and Immunisation Education, Children's Hospital, Headington, Oxford, UK</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Snape, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.GPPAD.org</url>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>T1D</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>oral insulin</keyword>
  <keyword>oral tolerance</keyword>
  <keyword>autoantigen</keyword>
  <keyword>self tolerance</keyword>
  <keyword>prevention</keyword>
  <keyword>at risk for developing type 1 diabetes</keyword>
  <keyword>juvenile diabetes</keyword>
  <keyword>autoimmune diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

